Clinical outcomes following injections of leukocyte-rich platelet-rich plasma in osteoarthritis patients

BACKGROUND: Scientists are trying to discover how to repair cartilage defects in knee osteoarthritis (KOA). In our previous study, we found a fibrocartilage-rich cover over the defective portions of cartilage after administering leukocyte-rich platelet-rich plasma (LR-PRP). This study aimed to investigate the efficacy of multiple injections of LR-PRP for the treatment of KOA and determine an LR-PRP treatment protocol for KOA in actual clinical practice. HYPOTHESIS: We hypothesized that using abundant LR-PRP would improve outcomes in patients with KOA. STUDY DESIGN: Prospective, cross-sectional, interventional, randomized trial. METHODS: Intra-articular LR-PRP injections were administered to 50 knees. Patients received six injections of LR-PRP in total, which were administered at 4-week intervals. Patients were evaluated based on clinical outcomes, including visual analog scale (VAS) scores, Knee injury and Osteoarthritis Outcome Scores (KOOS), and magnetic resonance images (MRI) and radiographic findings before treatment and at 3 and 6 months after treatment. We investigated the recurrence of pain and presence/absence of MRI changes. Furthermore, we examined the Outcome Measures In Rheumatology-Osteoarthritis Research Society International (OMERACT-OARSI) responder criteria. RESULTS: The mean improvement rate, as assessed by VAS, was 61.6% (P < .0001). Concerning OMERACT-OARSI, 37 of 50 knees (74%) were considered responders. There was a significant difference in the follow-up MRI findings, as assessed by the MRI Osteoarthritis Knee Score for bone marrow lesions (P < .007). No significant difference in osteoarthritis grade was observed. CONCLUSION: Our LR-PRP procedure resulted in 74% of knees being classified as responders, regardless of the degree of knee deformation. Multiple injections of LR-PRP was effective for advanced grades of KOA. Thus, based on the results of our study, we believe that LR-PRP should be implemented as an additional conservative treatment option for non-operative management of OA. TRIAL REGISTRATION: Japan Medical Association Center for Clinical Trials (JMA-XXX).